.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Novartis
Queensland Health
Federal Trade Commission
UBS
Argus Health
US Department of Justice
Julphar
Daiichi Sankyo
QuintilesIMS

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022204

« Back to Dashboard
NDA 022204 describes GELNIQUE, which is a drug marketed by Allergan Sales Llc and is included in two NDAs. It is available from three suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the GELNIQUE profile page.

The generic ingredient in GELNIQUE is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.

Summary for NDA: 022204

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Genitourinary Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 022204

Suppliers and Packaging for NDA: 022204

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL 022204 NDA Allergan, Inc. 0023-5812 0023-5812-30 1 BOTTLE, PUMP in 1 CARTON (0023-5812-30) > 30 g in 1 BOTTLE, PUMP
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL 022204 NDA Allergan, Inc. 0023-5861 0023-5861-11 30 PACKET in 1 CARTON (0023-5861-11) > 1 g in 1 PACKET

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:GEL;TRANSDERMALStrength10%(100MG/PACKET)
Approval Date:Jan 27, 2009TE:RLD:Yes
Patent:8,920,392Patent Expiration:Mar 26, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
Patent:9,259,388Patent Expiration:Nov 6, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
Patent:7,029,694Patent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Argus Health
Fuji
Colorcon
Fish and Richardson
Covington
US Army
Farmers Insurance
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot